Pharmaceutical Compositions for the Treatment of Attention Deficit Hyperactivity Disorder Comprising Flibanserin
AssigneeBoehringer Ingelheim International GmbH
InventorsBoris Ferger, Angelo Ceci
Life of this patent
Estimating the term…
Abstract
The invention relates to new pharmaceutical compositions for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and methods for the preparation thereof. In a preferred embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment ADHD and methods for the preparation thereof.
Claims20
1-21. (canceled)
22) A pharmaceutical composition comprising a therapeutically effective amount of flibanserin 1, as one active ingredient, optionally in form the free base or a pharmacologically acceptable acid addition salt thereof, and a therapeutically effective amount of a second active ingredient 2 suitable for the treatment or prevention of Attention Deficit Hyperactivity Disorder (ADHD), optionally in combination with a pharmaceutically acceptable excipient.
34) A method for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) comprising the administration of a therapeutically effective amount of flibanserin 1, as one active ingredient, optionally in form the free base or a pharmacologically acceptable acid addition salt thereof, and a therapeutically effective amount of a second active ingredient 2, which is suitable for the treatment or prevention of Attention Deficit Hyperactivity Disorder (ADHD), optionally in combination with a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.